<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-10-29" updated="2020-01-02">
  <drugbank-id primary="true">DB09287</drugbank-id>
  <name>Polyethylene glycol</name>
  <description>Polyethylene glycol is a polyether compound used for many purposes ranging from industrial manufacturing processes to medicine. PEG is the basis of a number of laxatives (e.g., macrogol-containing products, such as Movicol and polyethylene glycol 3350, or SoftLax, MiraLAX,ClearLAX, Osmolax or GlycoLax). Irrigation of the bowel with polyethylene glycol and electrolytes is included in bowel preparation therapy, normally indicated before a colonoscopy to ensure adequate visualization of the bowel. Therapeutic classification is as an Osmotic Laxative that works by drawing water into the lumen of the intestinal tract. Shown to decrease consistency and increase weight of stool in constipated patients at low doses.</description>
  <cas-number>25322-68-3</cas-number>
  <unii>3WJQ0SDW1A</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18713</ref-id>
        <pubmed-id>10703152</pubmed-id>
        <citation>Hammer HF, Hammer J, Gasche C: [Polyethylene glycol (Macrogol)--an overview of its use in diagnosis and therapy of gastrointestinal diseases]. Wien Klin Wochenschr. 2000 Jan 28;112(2):53-60.</citation>
      </article>
      <article>
        <ref-id>A18714</ref-id>
        <pubmed-id>23425050</pubmed-id>
        <citation>Muller-Lissner S: Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):391-401. doi: 10.1517/17425255.2013.773972. Epub 2013 Feb 21.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6421</ref-id>
        <title>PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209381s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L6424</ref-id>
        <title>PegaLAX (polyethylene glycol 3350) 2017 Canadian Prescribing Information</title>
        <url>https://aralez.com/wp-content/uploads/2018/03/PEGALAX-Prescribing-Information-22-MARCH-2017.pdf</url>
      </link>
      <link>
        <ref-id>L6427</ref-id>
        <title>NIH US National Library of Medicine MedlinePlus: Polyethylene Glycol 3350 Profile</title>
        <url>https://medlineplus.gov/druginfo/meds/a603032.html</url>
      </link>
      <link>
        <ref-id>L6430</ref-id>
        <title>Electronic Medicines Compendium: PegLax (Macrogol 4000) Monograph</title>
        <url>https://www.medicines.org.uk/emc/product/3170/smpc</url>
      </link>
      <link>
        <ref-id>L6433</ref-id>
        <title>NCBI StatPearls [Internet]: Bowel Preparation</title>
        <url>https://www.ncbi.nlm.nih.gov/books/NBK535368/</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used to treat and prevent constipation.</indication>
  <pharmacodynamics>The pharmacological rationale for the use of polyethylene glycol (PEG) in gastroenterology is its inverse relation between molecular mass and intestinal absorbability, with practically no intestinal absorption at molecular masses exceeding 3000, its lack of intestinal enzymatic degradation or bacterial metabolism, and its water binding capacity.</pharmacodynamics>
  <mechanism-of-action>Polyethylene glycol functions as an osmotic agent, causing excess water to be retained in the stool, stimulating a bowel movement.</mechanism-of-action>
  <toxicity>Oral LD50 is &gt; 50 gm/Kg in mice, rats, and rabbits. &#13;
In the event of overdosage, diarrhea would be the expected major event. Massive ingestion, prolonged IV infusion, and prolonged application of low weight PEG products have been associated with metabolic acidosis and renal injury. Hypercalcemia could also occur.</toxicity>
  <metabolism>Lack of intestinal enzymatic degradation or bacterial metabolism.</metabolism>
  <absorption>Usually the high and intermediate molecular weight polyethylene glycol are poorly absorbed after oral administration. </absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001656</drugbank-id>
      <name>Polyoxyethylene 23 lauryl ether</name>
      <unii>N72LMW566G</unii>
      <cas-number/>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Macrogol</synonym>
    <synonym language="english" coder="">Macrogol 3350</synonym>
    <synonym language="english" coder="">Macrogol 4000</synonym>
    <synonym language="english" coder="">Macrogol 6000</synonym>
    <synonym language="english" coder="">PEG</synonym>
    <synonym language="english" coder="">Polyethylene glycol 3350</synonym>
    <synonym language="english" coder="">Polyethylene glycol 4000</synonym>
    <synonym language="english" coder="">Polyethylene glycol 6000</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aquasite Dps</name>
      <labeller>Ciba Vision</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02029901</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2000-11-08</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Basic Care Clearlax</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-7306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Berkley and Jensen Clearlax</name>
      <labeller>BJWC</labeller>
      <ndc-id/>
      <ndc-product-code>68391-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>BET-R-Prep</name>
      <labeller>Satius Pharmaceuticals, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71890-704</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bi-peglyte</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326302</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution; Tablet, delayed release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Care One Clearlax</name>
      <labeller>American Sales Company</labeller>
      <ndc-id/>
      <ndc-product-code>41520-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clarilax</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464136</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Clear Lax</name>
      <labeller>H E B</labeller>
      <ndc-id/>
      <ndc-product-code>37808-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Lax</name>
      <labeller>Meijer Distribution</labeller>
      <ndc-id/>
      <ndc-product-code>41250-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on>2013-10-19</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Lax</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-939</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Lax</name>
      <labeller>Meijer Distribution Inc</labeller>
      <ndc-id/>
      <ndc-product-code>41250-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Lax Original Prescription Strength</name>
      <labeller>Hyvee</labeller>
      <ndc-id/>
      <ndc-product-code>42507-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-11</started-marketing-on>
      <ended-marketing-on>2012-02-10</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Lax Original Prescription Strength</name>
      <labeller>HYVEE INC</labeller>
      <ndc-id/>
      <ndc-product-code>42507-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-11</started-marketing-on>
      <ended-marketing-on>2020-03-23</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clear Laxative</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-887</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-02</started-marketing-on>
      <ended-marketing-on>2012-02-10</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0287</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Shopko Stores Operating Co., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>37012-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Publix Super Markets Inc</labeller>
      <ndc-id/>
      <ndc-product-code>56062-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ClearLax</name>
      <labeller>Walmart Stores</labeller>
      <ndc-id/>
      <ndc-product-code>49035-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2017-06-19</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Perrigo International</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02324989</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 %</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Hannaford Brothers Company</labeller>
      <ndc-id/>
      <ndc-product-code>41268-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2014-02-09</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clearlax</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-143</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Clenz-Lyte</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0427</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-07</started-marketing-on>
      <ended-marketing-on>2010-06-07</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>ANDA090769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Colyte</name>
      <labeller>Alaven Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>68220-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-01</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>NDA018983</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Colyte</name>
      <labeller>MEDA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0037-6820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric</route>
      <fda-application-number>NDA018983</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Colyte</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00677442</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Colyte with flavor packs</name>
      <labeller>Alaven Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>68220-130</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-04-07</started-marketing-on>
      <ended-marketing-on>2016-08-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>NDA018983</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Comfilax</name>
      <labeller>Cellchem Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460297</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dg Health Clearlax</name>
      <labeller>DOLGENCORP, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55910-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dulcolax Balance</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2013-10-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EasyLax</name>
      <labeller>Best Choice (Valu Merchandisers Company)</labeller>
      <ndc-id/>
      <ndc-product-code>63941-332</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-03-31</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EasyLAX</name>
      <labeller>WinCo Foods, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67091-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on>2020-12-30</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EasyLAX</name>
      <labeller>Valu Merchandisers Company</labeller>
      <ndc-id/>
      <ndc-product-code>63941-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EasyLAX</name>
      <labeller>Marc Glassman, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68998-465</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on>2021-12-30</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Electropeg Solution</name>
      <labeller>Technilab Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230825</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-20</started-marketing-on>
      <ended-marketing-on>1999-09-27</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Emolax</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374137</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Emolax 3350</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492121</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Equaline Clearlax</name>
      <labeller>SUPERVALU INC</labeller>
      <ndc-id/>
      <ndc-product-code>41163-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Equate Clear Lax</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exchange Select ClearLax</name>
      <labeller>Army &amp; Air Force Exchange Service</labeller>
      <ndc-id/>
      <ndc-product-code>55301-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EZ2go</name>
      <labeller>Valley Medical Products,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76470-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EZ2go</name>
      <labeller>Valley Medical Products,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76470-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EZ2go Hydro-Lax</name>
      <labeller>Valley Medical Products, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76470-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-01</started-marketing-on>
      <ended-marketing-on>2012-02-06</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>EZ2go PEG 3350</name>
      <labeller>Valley Medical Products,LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76470-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Wellness Laxative</name>
      <labeller>Family Dollar Services Inc</labeller>
      <ndc-id/>
      <ndc-product-code>55319-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fulton Street Market Clearlax</name>
      <labeller>Access Business Group</labeller>
      <ndc-id/>
      <ndc-product-code>10056-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-11</started-marketing-on>
      <ended-marketing-on>2014-08-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Atlantic Biologicals Corps</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>43386-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Preferred Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-9849</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-368</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilax</name>
      <labeller>Directrx</labeller>
      <ndc-id/>
      <ndc-product-code>61919-542</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GaviLyte - C TM</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>43386-060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090186</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GaviLyte - N</name>
      <labeller>Lupin Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>43386-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gavilyte G Tm</name>
      <labeller>Lupin Pharmaceuticals,Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GaviLyte-H and Bisacodyl</name>
      <labeller>Gavis Pharmaceuticals, LLC.</labeller>
      <ndc-id/>
      <ndc-product-code>43386-071</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA202217</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gentle Lax</name>
      <labeller>Kroger Company</labeller>
      <ndc-id/>
      <ndc-product-code>30142-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gialax</name>
      <labeller>Phlight Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70569-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GlycoLax Osmotic Laxative</name>
      <labeller>Lannett Company, Inc..</labeller>
      <ndc-id/>
      <ndc-product-code>62175-190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090600</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GoLYTELY</name>
      <labeller>Braintree Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52268-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GoLYTELY</name>
      <labeller>Braintree Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52268-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GoLYTELY</name>
      <labeller>Braintree Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52268-700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-07-13</started-marketing-on>
      <ended-marketing-on>2022-05-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GoLYTELY</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Golytely Gi Lavage Solution</name>
      <labeller>Braintree Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00652512</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Good Neighbor Pharmacy ClearLax</name>
      <labeller>Amerisource Bergen</labeller>
      <ndc-id/>
      <ndc-product-code>46122-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Good Sense Clear Lax</name>
      <labeller>L. Perrigo Company</labeller>
      <ndc-id/>
      <ndc-product-code>0113-0306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HalfLytely and Bisacodyl</name>
      <labeller>Braintree Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>52268-522</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-31</started-marketing-on>
      <ended-marketing-on>2012-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021551</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HalfLytely and Bisacodyl</name>
      <labeller>Braintree Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>52268-521</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-31</started-marketing-on>
      <ended-marketing-on>2012-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021551</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HalfLytely and Bisacodyl Bowel Prep with Flavor Packs</name>
      <labeller>Braintree Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>52268-523</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-02</started-marketing-on>
      <ended-marketing-on>2013-06-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021551</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Harris Teeter Clearlax</name>
      <labeller>Harris Teeter, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69256-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Clearlax</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0153</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Health Mart Clearlax</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0298</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthy Accents Clear Lax</name>
      <labeller>DZA Brands LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55316-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-06</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthylax</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-01</started-marketing-on>
      <ended-marketing-on>2020-09-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Healthylax</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humana Pharmacy Clear Laxative</name>
      <labeller>Humana Pharmacy, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70925-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hydralax</name>
      <labeller>Juno Otc Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473119</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-electropeg</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02406780</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamp-electropeg With Flavour Packet</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02406799</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamplyte</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02368234</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Jamplyte 280</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02378329</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kirkland Signature Laxaclear Original Prescription Strength</name>
      <labeller>Costco Wholesale Company</labeller>
      <ndc-id/>
      <ndc-product-code>63981-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Klean-prep</name>
      <labeller>Richmond Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00741175</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-09</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Klean-prep</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02147793</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-05-12</started-marketing-on>
      <ended-marketing-on>2017-06-15</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lax-A-day</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317680</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lax-A-day Men</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455617</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lax-A-day Pharma</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02453193</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lax-relief</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463970</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Laxaclear</name>
      <labeller>Perrigo International</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391007</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Laxative</name>
      <labeller>Fred's Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55315-369</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on>2021-03-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Laxative</name>
      <labeller>Chain Drug Consortium, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68016-726</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Laxative</name>
      <labeller>Rite Aid Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11822-0306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Laxative Clear</name>
      <labeller>Western Family Foods</labeller>
      <ndc-id/>
      <ndc-product-code>55312-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-24</started-marketing-on>
      <ended-marketing-on>2018-10-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Clear Lax original prescription strength</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>37205-612</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader ClearLax</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>49781-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-26</started-marketing-on>
      <ended-marketing-on>2015-06-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leader Clearlax</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lubricating Nasal Gel</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02220806</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lubricating Nasal Mist</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00551813</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lubricating Nasal Mist</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00732230</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lyteprep</name>
      <labeller>Therapex Division De E Z Em Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239569</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-01-25</started-marketing-on>
      <ended-marketing-on>2005-09-26</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>M-peg 3350</name>
      <labeller>Mantra Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02450070</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Members Mark clearlax</name>
      <labeller>SAM'S WEST INC</labeller>
      <ndc-id/>
      <ndc-product-code>68196-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mighty Lax</name>
      <labeller>Konsyl Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0224-1890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MiraLAX</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5035</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>NDA022015</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MiraLAX</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-7268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>NDA022015</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MiraLAX</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-7234</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>NDA022015</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MiraLAX</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-7341</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>NDA022015</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MiraLAX</name>
      <labeller>Bayer Healthcare Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>11523-4357</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>NDA022015</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mix-In Laxative Packets</name>
      <labeller>WAL-MART STORES INC</labeller>
      <ndc-id/>
      <ndc-product-code>49035-906</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Moviprep</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5890</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021881</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MoviPrep</name>
      <labeller>Salix Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65649-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021881</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>MoviPrep</name>
      <labeller>Aralez Pharmaceuticals Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02359499</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Natura-lax</name>
      <labeller>Chain Drug Marketing Association</labeller>
      <ndc-id/>
      <ndc-product-code>63868-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NuLYTELY</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-4233</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019797</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NuLYTELY With Flavor Packs</name>
      <labeller>Braintree Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52268-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019797</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ocl Solution</name>
      <labeller>Abbott</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00709298</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2007-07-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Osmotic Laxative</name>
      <labeller>Lidl Us, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>71141-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-31</started-marketing-on>
      <ended-marketing-on>2021-12-31</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PCP 100 Kit</name>
      <labeller>Asclemed Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76420-625</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg</name>
      <labeller>Biocellerex, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69801-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-14</started-marketing-on>
      <ended-marketing-on>2016-01-05</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7982</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6422</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2526</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on>2020-05-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Medisca Pharmaceutique Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02358034</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 %</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5887</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on>2018-06-22</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg 3350</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Peg-3350</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6664</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-13</started-marketing-on>
      <ended-marketing-on>2013-06-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090409</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350 and Electrolytes</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6138</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350 and Electrolytes</name>
      <labeller>Affordable Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>10572-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350 and Electrolytes</name>
      <labeller>Affordable Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>10572-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019011</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350 and Electrolytes</name>
      <labeller>Lannett Company, Inc..</labeller>
      <ndc-id/>
      <ndc-product-code>62175-446</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA018983</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride</name>
      <labeller>Affordable Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>10572-302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride</name>
      <labeller>Affordable Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>10572-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA019797</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegalax</name>
      <labeller>Aralez Pharmaceuticals Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02328232</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Peglyte Powder</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00777838</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Peglyte Solution</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00777846</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-13</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Plenvu</name>
      <labeller>Salix Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>65649-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA209381</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Plenvu</name>
      <labeller>Salix Pharmaceuticals, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>65649-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA209381</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PMS-peglyte</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471590</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Poly-Prep</name>
      <labeller>Pure Tek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-839</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol</name>
      <labeller>Harmon Stores</labeller>
      <ndc-id/>
      <ndc-product-code>63940-762</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol (3350)</name>
      <labeller>CRH Medical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>69041-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-09-24</started-marketing-on>
      <ended-marketing-on>2015-10-16</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on>2020-10-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Metrics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10184-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on>2009-02-28</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Strides Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>59556-762</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-6707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Gericare Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57896-490</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076652</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Breckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on>2021-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076652</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Perrigo New York Inc</labeller>
      <ndc-id/>
      <ndc-product-code>45802-868</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Golden State Medical Supply</labeller>
      <ndc-id/>
      <ndc-product-code>60429-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-08</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-8184</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Breeckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-961</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Breeckenridge Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51991-962</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2099-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090567</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Lake Erie Medical &amp; Surgical Supply DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>35356-544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Lannett Company, Inc..</labeller>
      <ndc-id/>
      <ndc-product-code>62175-442</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076652</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>61786-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-05</started-marketing-on>
      <ended-marketing-on>2018-05-04</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-6921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Aurohealth LLC</labeller>
      <ndc-id/>
      <ndc-product-code>58602-805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA209017</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene glycol 3350</name>
      <labeller>Discount Drug Mart</labeller>
      <ndc-id/>
      <ndc-product-code>53943-742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>71205-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Gericare Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>57896-489</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-6920</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Atlantic Biologicals Corps.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0457</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077706</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Lannett Company, Inc..</labeller>
      <ndc-id/>
      <ndc-product-code>62175-195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090600</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Marlex Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>10135-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene glycol 3350</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6931</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Emcure Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>14539-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202071</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077893</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 and Electrolytes</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0378-6669</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-02</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090928</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 and Electrolytes</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0428</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2010-02-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>60 g/1L</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090712</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 and electrolytes - Unflavored</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-765</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204558</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES With flavor packs</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0426</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2010-02-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>60 g/1L</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090712</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 and electrolytes with Lemon Flavor</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-766</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204558</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 and electrolyteswith Orange Flavor</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-767</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204558</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 Nf</name>
      <labeller>Nuvo Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42576-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 Nf</name>
      <labeller>Sunrise Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>11534-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-06-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 Nf</name>
      <labeller>Woodward Pharma Services Llc</labeller>
      <ndc-id/>
      <ndc-product-code>69784-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350 NF PEGyLAX</name>
      <labeller>Martin Ekwealor Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58607-700</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350, NF Powder for Solution, Laxative</name>
      <labeller>Nexgen Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0722-7116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1d</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350, NF Powder for Solution, Laxative</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-598</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/1g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090812</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE and POTASSIUM CHLORIDE</name>
      <labeller>Paddock Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0574-0425</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-02-25</started-marketing-on>
      <ended-marketing-on>2012-04-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079232</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride - Unflavored</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-768</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204559</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride with Lemon Flavor</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-769</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204559</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride with Orange Flavor</name>
      <labeller>Strides Pharma Science Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64380-770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA204559</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol-3350</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-312</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA091077</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol-3350 and Electrolytes</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090231</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol-3350 and Electrolytes with Flavor Pack</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-060</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090186</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polyethylene Glycol-3350, Sodium Chloride, Potassium Chloride and Sodium Bicarbonate</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA090019</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Polylax</name>
      <labeller>Seaford Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02330326</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-26</started-marketing-on>
      <ended-marketing-on>2016-06-16</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Preferred Plus ClearLax</name>
      <labeller>Kinray</labeller>
      <ndc-id/>
      <ndc-product-code>61715-150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Prolax - Pws</name>
      <labeller>Rivex Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02147785</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-21</started-marketing-on>
      <ended-marketing-on>2007-10-15</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Purelax</name>
      <labeller>Perrigo International</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02415054</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 %</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Purelax</name>
      <labeller>CVS PHARMACY</labeller>
      <ndc-id/>
      <ndc-product-code>59779-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Purelax</name>
      <labeller>CVS Health</labeller>
      <ndc-id/>
      <ndc-product-code>59779-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-02</started-marketing-on>
      <ended-marketing-on>2013-01-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relaxa</name>
      <labeller>Medexus Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346672</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Restoralax</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02318164</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rhinaris Nasal Gel</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352699</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rhinaris Nasal Mist</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02354551</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rhinedrine Lubricant Nasal Gel</name>
      <labeller>Jamieson Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02078937</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-12-11</started-marketing-on>
      <ended-marketing-on>2004-07-01</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>rugby PEG 3350</name>
      <labeller>RUGBY LABORATORIES</labeller>
      <ndc-id/>
      <ndc-product-code>0536-1052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Salinex Nasal Lubricant</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01910701</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2012-08-02</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Salinex Nasal Lubricant Gel</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00779296</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>2012-08-02</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Salinol Sol 160mg</name>
      <labeller>Laboratoires Charton Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00779288</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1999-01-16</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Secaris</name>
      <labeller>Pendopharm Division Of Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00551805</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ShopRite Clear Laxative</name>
      <labeller>Wakefern Food Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>41190-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Signature Care Clearlax</name>
      <labeller>Safeway</labeller>
      <ndc-id/>
      <ndc-product-code>21130-847</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Simply Right clearLAX</name>
      <labeller>Sam's West, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68196-411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-19</started-marketing-on>
      <ended-marketing-on>2016-11-27</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smart Sense Clearlax</name>
      <labeller>Kmart Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>49738-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smooth Lax</name>
      <labeller>Walgreen Company</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smooth Lax Original Prescription Strength</name>
      <labeller>Walgreen</labeller>
      <ndc-id/>
      <ndc-product-code>0363-0181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-08</started-marketing-on>
      <ended-marketing-on>2012-12-14</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Suclear</name>
      <labeller>Braintree Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>52268-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-18</started-marketing-on>
      <ended-marketing-on>2016-08-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA203595</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Clearlax</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>49348-893</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sunmark Clearlax</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1447</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare ClearLax</name>
      <labeller>Topco Associates LLC</labeller>
      <ndc-id/>
      <ndc-product-code>36800-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Topcare ClearLax</name>
      <labeller>Topco Associates</labeller>
      <ndc-id/>
      <ndc-product-code>36800-181</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2012-09-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TriLyte with Flavor Packs</name>
      <labeller>Wallace Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51525-6831</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>ANDA076491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>TRILYTE with flavor packs</name>
      <labeller>Alaven Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>68220-131</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Nasogastric; Oral</route>
      <fda-application-number>ANDA076491</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Up and Up Powderlax</name>
      <labeller>TARGET Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>11673-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visine Extra Ophthalmic Sol</name>
      <labeller>Pfizer Canada Inc., Consumer Healthcare Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01942468</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Welby ClearLax</name>
      <labeller>Aldi, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>64024-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>17 g/17g</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090685</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Fortrans</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>GlycoLax</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>TriLyte</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>TRILYTE with flavor packs</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol-3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol-3350, Sodium Chloride, Potassium Chloride and Sodium Bicarbonate</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol-3350 and Electrolytes with Flavor Pack</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Moviprep</name>
      <ingredients>Ascorbic acid + Polyethylene glycol + Potassium chloride + Sodium ascorbate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350, NF Powder for Solution, Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>GoLYTELY</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>NuLYTELY</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EZ2go Hydro-Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg-3350</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>HalfLytely and Bisacodyl</name>
      <ingredients>Bisacodyl + Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>HalfLytely and Bisacodyl</name>
      <ingredients>Bisacodyl + Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 NF PEGyLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Natura-lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Dulcolax Balance</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Laxative Clear</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clenz-Lyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol (3350)</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE and POTASSIUM CHLORIDE</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES With flavor packs</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>HalfLytely and Bisacodyl Bowel Prep with Flavor Packs</name>
      <ingredients>Bisacodyl + Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>GaviLyte-H and Bisacodyl</name>
      <ingredients>Bisacodyl + Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Suclear</name>
      <ingredients>Magnesium sulfate + Polyethylene glycol + Potassium chloride + Potassium sulfate + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Simply Right clearLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Leader ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Fulton Street Market Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Poly-Prep</name>
      <ingredients>Bisacodyl + Hydrocortisone acetate + Lidocaine + Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Purelax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax Original Prescription Strength</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>GaviLyte - C TM</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 Nf</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>GaviLyte - N</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Topcare ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 Nf</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Smooth Lax Original Prescription Strength</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>PCP 100 Kit</name>
      <ingredients>Bisacodyl + Magnesium citrate + Metoclopramide + Petrolatum + Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>BET-R-Prep</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>GlycoLax Osmotic Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Colyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol-3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Colyte with flavor packs</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 Nf</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg</name>
      <ingredients>Polyethylene glycol + Polyethylene glycol 400</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350 and Electrolytes</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax Original Prescription Strength</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gialax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MiraLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Colyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EZ2go</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EZ2go PEG 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EZ2go</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Topcare ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Leader Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Up and Up Powderlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MiraLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MiraLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MiraLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MiraLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>rugby PEG 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Smooth Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Healthylax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Plenvu</name>
      <ingredients>Ascorbic acid + Polyethylene glycol + Polyethylene glycol + Potassium chloride + Potassium chloride + Sodium ascorbate + Sodium chloride + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Plenvu</name>
      <ingredients>Ascorbic acid + Polyethylene glycol + Polyethylene glycol + Potassium chloride + Potassium chloride + Sodium ascorbate + Sodium chloride + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Good Sense Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>TriLyte with Flavor Packs</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Welby ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Sunmark Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Health Mart Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Mighty Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Signature Care Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EasyLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EasyLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350, NF Powder for Solution, Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Basic Care Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Mix-In Laxative Packets</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Osmotic Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Berkley and Jensen Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gavilyte G Tm</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Purelax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>GoLYTELY</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>GoLYTELY</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>GoLYTELY</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Kirkland Signature Laxaclear Original Prescription Strength</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Healthylax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EasyLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gavilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Leader Clear Lax original prescription strength</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Equate Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Family Wellness Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Good Neighbor Pharmacy ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Gentle Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride - Unflavored</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride with Lemon Flavor</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride with Orange Flavor</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>MoviPrep</name>
      <ingredients>Ascorbic acid + Polyethylene glycol + Potassium chloride + Sodium ascorbate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>ShopRite Clear Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Dg Health Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Equaline Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Exchange Select ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Preferred Plus ClearLax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Members Mark clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Care One Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Healthy Accents Clear Lax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>NuLYTELY With Flavor Packs</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Humana Pharmacy Clear Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Harris Teeter Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Smart Sense Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>EasyLAX</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 and electrolytes - Unflavored</name>
      <ingredients>Chloric acid + Polyethylene glycol + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 and electrolytes with Lemon Flavor</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polyethylene Glycol 3350 and electrolyteswith Orange Flavor</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Laxative</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lubricating Nasal Gel</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Secaris</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Golytely Gi Lavage Solution</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Colyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Clearlax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Bi-peglyte</name>
      <ingredients>Bisacodyl + Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Pegalax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Rhinaris Nasal Gel</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Rhinaris Nasal Mist</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>MoviPrep</name>
      <ingredients>Ascorbic acid + Polyethylene glycol + Potassium chloride + Sodium ascorbate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Purelax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Peglyte Powder</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Salinol Sol 160mg</name>
      <ingredients>Polyethylene glycol + Propylene glycol + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Salinex Nasal Lubricant Gel</name>
      <ingredients>Polyethylene glycol + Propylene glycol + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Salinex Nasal Lubricant</name>
      <ingredients>Polyethylene glycol + Propylene glycol + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Aquasite Dps</name>
      <ingredients>Dextran + Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Rhinedrine Lubricant Nasal Gel</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Prolax - Pws</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Visine Extra Ophthalmic Sol</name>
      <ingredients>Polyethylene glycol + Tetryzoline</ingredients>
    </mixture>
    <mixture>
      <name>Electropeg Solution</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Lyteprep</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Klean-prep</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Ocl Solution</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Peglyte Solution</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Jamplyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Jamplyte 280</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Laxaclear</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-electropeg</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Jamp-electropeg With Flavour Packet</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Emolax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Polylax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lax-A-day Pharma</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lax-A-day Men</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lubricating Nasal Mist</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lubricating Nasal Mist</name>
      <ingredients>Polyethylene glycol + Propylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Relaxa</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lax-A-day</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>M-peg 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Lax-relief</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Clarilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Klean-prep</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Restoralax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Comfilax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>PMS-peglyte</name>
      <ingredients>Polyethylene glycol + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Hydralax</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
    <mixture>
      <name>Emolax 3350</name>
      <ingredients>Polyethylene glycol</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Drug Delivery Systems</category>
      <mesh-id>D016503</mesh-id>
    </category>
    <category>
      <category>Drugs for Constipation</category>
      <mesh-id/>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Excipients</category>
      <mesh-id>D005079</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Laxatives</category>
      <mesh-id>D054368</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Osmotic Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Osmotic Laxatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pharmaceutic Aids</category>
      <mesh-id>D010592</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Vehicles</category>
      <mesh-id>D014677</mesh-id>
    </category>
    <category>
      <category>Polyethylene Glycols</category>
      <mesh-id>D011092</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Solvents</category>
      <mesh-id>D012997</mesh-id>
    </category>
    <category>
      <category>Stimulation Large Intestine Fluid/Electrolyte Secretion</category>
      <mesh-id/>
    </category>
    <category>
      <category>Surface-Active Agents</category>
      <mesh-id>D013501</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution; tablet, delayed release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>100 %</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Topical</route>
      <strength>17 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Nasogastric</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Topical</route>
      <strength>17 g/17g</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength>17 g/17g</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol, metered</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>17 g/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>60 g/1L</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>17 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>17 g/1d</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength>17 g/17g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Nasogastric; Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A06AD15">
      <level code="A06AD">Osmotically acting laxatives</level>
      <level code="A06A">DRUGS FOR CONSTIPATION</level>
      <level code="A06">DRUGS FOR CONSTIPATION</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A06AD65">
      <level code="A06AD">Osmotically acting laxatives</level>
      <level code="A06A">DRUGS FOR CONSTIPATION</level>
      <level code="A06">DRUGS FOR CONSTIPATION</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>56:12.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09287.pdf?1446147037</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09287.pdf?1557954452</msds>
  <patents>
    <patent>
      <number>7291324</number>
      <country>United States</country>
      <approved>2007-11-06</approved>
      <expires>2022-10-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7169381</number>
      <country>United States</country>
      <approved>2007-01-30</approved>
      <expires>2024-09-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7658914</number>
      <country>United States</country>
      <approved>2010-02-09</approved>
      <expires>2024-09-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9326969</number>
      <country>United States</country>
      <approved>2016-05-03</approved>
      <expires>2033-09-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9592252</number>
      <country>United States</country>
      <approved>2017-03-14</approved>
      <expires>2032-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9707297</number>
      <country>United States</country>
      <approved>2017-07-18</approved>
      <expires>2033-09-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8999313</number>
      <country>United States</country>
      <approved>2015-04-07</approved>
      <expires>2033-09-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10016504</number>
      <country>United States</country>
      <approved>2018-07-10</approved>
      <expires>2033-09-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with GlycoPEG-GCSF.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegpleranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegsunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginesatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be decreased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be decreased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Clidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of adverse effects can be increased when Torasemide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of adverse effects can be increased when Triamterene is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of adverse effects can be increased when Metolazone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of adverse effects can be increased when Benzthiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of adverse effects can be increased when Amiloride is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of adverse effects can be increased when Furosemide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of adverse effects can be increased when Eplerenone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Methazolamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of adverse effects can be increased when Indapamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Acetazolamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The risk or severity of adverse effects can be increased when Conivaptan is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Bumetanide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Zonisamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of adverse effects can be increased when Diazoxide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of adverse effects can be increased when Polythiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The risk or severity of adverse effects can be increased when Quinethazone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The risk or severity of adverse effects can be increased when Drospirenone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The risk or severity of adverse effects can be increased when Theobromine is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of adverse effects can be increased when Piretanide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tienilic acid is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>The risk or severity of adverse effects can be increased when Ularitide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The risk or severity of adverse effects can be increased when Indisulam is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of adverse effects can be increased when Azosemide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>The risk or severity of adverse effects can be increased when Canrenoic acid is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Empagliflozin is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Potassium citrate is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of adverse effects can be increased when Efonidipine is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>The risk or severity of adverse effects can be increased when Mersalyl is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The risk or severity of adverse effects can be increased when Isosorbide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>The risk or severity of adverse effects can be increased when Canrenone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>The risk or severity of adverse effects can be increased when Rolofylline is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>The risk or severity of adverse effects can be increased when Spiradoline is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of adverse effects can be increased when Cicletanine is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>The risk or severity of adverse effects can be increased when Meticrane is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The risk or severity of adverse effects can be increased when Ibopamine is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>The risk or severity of adverse effects can be increased when Mefruside is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of adverse effects can be increased when Mebutizide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>The risk or severity of adverse effects can be increased when Clorexolone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Clofenamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>The risk or severity of adverse effects can be increased when Fenquizone is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>The risk or severity of adverse effects can be increased when Clopamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The risk or severity of adverse effects can be increased when Muzolimine is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The risk or severity of adverse effects can be increased when Xipamide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The risk or severity of adverse effects can be increased when Epitizide is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The risk or severity of adverse effects can be increased when Bromotheophylline is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>The risk or severity of adverse effects can be increased when Potassium is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trimethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hydromorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Desomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Benzhydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cyclopentolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Talbutal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Metharbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Chloroprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Barbituric acid derivative.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The risk or severity of adverse effects can be increased when Sorbitol is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The risk or severity of adverse effects can be increased when Dantron is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenisatin is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Bisacodyl is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The risk or severity of adverse effects can be increased when Picosulfuric acid is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Carboxymethylcellulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Plantago seed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Castor oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sennosides.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Lactitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Lactulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Mineral oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Docusate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Methylcellulose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Pentaerithrityl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium tartrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, monobasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Phenolphthalein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Bisoxatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Lubiprostone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Linaclotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Plecanatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Deacetylbisacodyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Zinc.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14516</drugbank-id>
      <name>Sodium cation</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14546</drugbank-id>
      <name>Sulfate ion</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sulfate ion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Plantago ovata seed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Phenylacetic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium acetate tetrahydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Monopotassium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Dipotassium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium fluorophosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13180</drugbank-id>
      <name>Gluconic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Gluconic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13743</drugbank-id>
      <name>Sodium aurotiosulfate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium aurotiosulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Potassium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14502</drugbank-id>
      <name>Sodium phosphate, dibasic</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, monobasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, dibasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Magnesium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Oxyphenisatin acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Calcium polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Emodin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Konjac mannan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09483</drugbank-id>
      <name>Potassium lactate</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Potassium lactate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Alloin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Frangula purshiana bark.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Dehydrocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Colchicine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Ranolazine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The excretion of Vincristine can be decreased when combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The serum concentration of Betrixaban can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Sirolimus can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Polyethylene glycol may decrease the excretion rate of Lefamulin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Gramicidin D can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Octreotide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Pravastatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Erythromycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Reserpine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Azithromycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Pantoprazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Eletriptan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The serum concentration of Nelfinavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Indinavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Topiramate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Venlafaxine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated estrogens can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Chlorambucil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Tenofovir disoproxil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Mitomycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Gefitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The serum concentration of Indomethacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Omeprazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Cetirizine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Terfenadine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Diltiazem can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Clobazam can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Mefloquine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vinorelbine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Grepafloxacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Amlodipine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Progesterone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The serum concentration of Sorafenib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Gemcitabine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Teniposide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Lansoprazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Prazosin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Quinine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Lenalidomide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Raloxifene can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The serum concentration of Celecoxib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Cimetidine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Haloperidol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Ritonavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Cisplatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Erlotinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Ciprofloxacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Toremifene can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Vinblastine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Fluticasone propionate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ivermectin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Chloroquine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Bisoprolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Imatinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Pentazocine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Verapamil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The serum concentration of Sumatriptan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Tamoxifen can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Losartan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Mycophenolate mofetil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The serum concentration of Nitrofurantoin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Esomeprazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Tetracycline can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Irinotecan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Olopatadine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Trifluoperazine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Loperamide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The serum concentration of Vardenafil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ondansetron can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The serum concentration of Acetylsalicylic acid can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Fexofenadine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dactinomycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Ezetimibe can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The serum concentration of Dipyridamole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The serum concentration of Ethinylestradiol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Cytarabine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Hydroxyurea can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Ketoconazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Melphalan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Ibuprofen can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Atazanavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Tegaserod can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Levofloxacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Itraconazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Arsenic trioxide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Levetiracetam can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Mitoxantrone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Sparfloxacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Clarithromycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Sitagliptin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Posaconazole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Paliperidone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Sunitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vecuronium can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Neostigmine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>The serum concentration of Testosterone propionate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>The serum concentration of Stanolone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Rhodamine 6G can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The serum concentration of Taurocholic acid can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Debrisoquine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Celiprolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Nilotinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The serum concentration of Belinostat can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Indacaterol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Telaprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Tolvaptan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The serum concentration of Rivaroxaban can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Panobinostat can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Odanacatib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Cabazitaxel can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The serum concentration of Ticagrelor can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Pitavastatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Crizotinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Vemurafenib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Regorafenib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Canagliflozin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The serum concentration of Levomilnacipran can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Dolutegravir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Idelalisib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Palbociclib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Olaparib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The serum concentration of Lenvatinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Ombitasvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Paritaprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>The serum concentration of Tenofovir alafenamide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Asunaprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Velpatasvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Curcumin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Tezacaftor can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Rifamycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The serum concentration of Ertugliflozin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The serum concentration of Revefenacin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Valspodar can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The serum concentration of Dacomitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The serum concentration of Glasdegib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Abemaciclib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Alpelisib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Voxilaprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The serum concentration of Letermovir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Erdafitinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Rucaparib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Lusutrombopag can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Pibrentasvir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Glecaprevir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>The serum concentration of Stanolone acetate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The serum concentration of Estradiol acetate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The serum concentration of Estradiol benzoate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The serum concentration of Estradiol cypionate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The serum concentration of Estradiol valerate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The serum concentration of Valinomycin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The serum concentration of Tenofovir can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Ivosidenib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Polyethylene glycol can be increased when it is combined with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Donepezil can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Entrectinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Fedratinib can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The serum concentration of Budesonide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Metoclopramide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Loratadine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Oxcarbazepine can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Anastrozole can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Lasmiditan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Trastuzumab deruxtecan can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Darolutamide can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15328</drugbank-id>
      <name>Ubrogepant</name>
      <description>The serum concentration of Ubrogepant can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>698</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13418</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910429</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03370</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Polyethylene_glycol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201478</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>